Skip to main content
. 2021 Oct 28;22(21):11641. doi: 10.3390/ijms222111641

Figure 3.

Figure 3

Measurement of IFN-α and CDM-3008 anti-SARS-CoV-2 activity using SARS-CoV-2 subreplicon expression vector-electroporated HeLa cells. (A) Schematic of the experimental design of electroporation with SARS-CoV-2 subreplicon expression vector and treatments of IFN-α and CDM-3008 for 1 day prior to luciferase and cell viability assays. (B,C) SARS-CoV-2 subreplicon-expressing HeLa cells were treated with 1–10,000 IU/mL IFN-α in B and 0.01-100 μM CDM-3008 in C for 1 day. Luciferase intensity (blue bars) and cell viability (orange lines) were measured and are shown as % of DMSO control. Error bars indicate SD (n = 3). * p < 0.05 and ** p < 0.01 (two-tailed t-test).